Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11431663rdf:typepubmed:Citationlld:pubmed
pubmed-article:11431663lifeskim:mentionsumls-concept:C0030590lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C0033429lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C0231220lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C0114771lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C0332189lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C1696465lld:lifeskim
pubmed-article:11431663lifeskim:mentionsumls-concept:C1708528lld:lifeskim
pubmed-article:11431663pubmed:issue1lld:pubmed
pubmed-article:11431663pubmed:dateCreated2001-6-29lld:pubmed
pubmed-article:11431663pubmed:abstractTextExisting drug therapies for paroxysmal supraventricular tachycardia (PSVT) have potentially serious adverse effects. Dofetilide, a pure class III antiarrhythmic agent, may offer an effective and safe alternative for treating PSVT. This study compared the efficacy and safety of dofetilide with that of propafenone and placebo in the prevention of PSVT.lld:pubmed
pubmed-article:11431663pubmed:languageenglld:pubmed
pubmed-article:11431663pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11431663pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11431663pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11431663pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11431663pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11431663pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11431663pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11431663pubmed:statusMEDLINElld:pubmed
pubmed-article:11431663pubmed:monthJullld:pubmed
pubmed-article:11431663pubmed:issn0002-8703lld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:DroszczWWlld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:SwiateckaGGlld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:Wnuk-WojnarA...lld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:TenderaMMlld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:Kawecka-Jaszc...lld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:MalolepszyJJlld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:Krzeminska-Pa...lld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:KozlowskiJ...lld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:RuzylloWWlld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:KulakowskiPPlld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:SzechinskiJJlld:pubmed
pubmed-article:11431663pubmed:authorpubmed-author:GraffOOlld:pubmed
pubmed-article:11431663pubmed:issnTypePrintlld:pubmed
pubmed-article:11431663pubmed:volume142lld:pubmed
pubmed-article:11431663pubmed:ownerNLMlld:pubmed
pubmed-article:11431663pubmed:authorsCompleteYlld:pubmed
pubmed-article:11431663pubmed:pagination93-8lld:pubmed
pubmed-article:11431663pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:meshHeadingpubmed-meshheading:11431663...lld:pubmed
pubmed-article:11431663pubmed:year2001lld:pubmed
pubmed-article:11431663pubmed:articleTitleEfficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.lld:pubmed
pubmed-article:11431663pubmed:affiliation3rd Department of Cardiology, Silesian Medical Academy, Katowice, Poland. mtendera@katowice.computerland.pllld:pubmed
pubmed-article:11431663pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11431663pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11431663pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11431663pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:11431663pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:11431663pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11431663lld:pubmed